[Translation] BHV3000-310: Phase 3: A Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of 75 mg BHV-3000 (Rimegepant) in the Acute Phase of Migraine
通过测量给药后2小时的疼痛消除作用和对最困扰的偏头痛有关症状(MBS)的消除作用这一共同主要终点来评估Rimegepant相比安慰剂在偏头痛急性期治疗方面的有效性。
[Translation] The efficacy of rimegepant versus placebo in the acute treatment of migraine was assessed by co-primary endpoints measuring pain relief at 2 hours post-dose and relief of the most bothersome migraine-related symptoms (MBS).